CareASSIST<sup>®</sup> Patient Support by Sanofi Genzyme. CareASSIST offers access support for eligible patients prescribed ELITEK

CareASSIST<sup>®</sup> ELITEK<sup>®</sup> (rasburicase)

CareASSIST<sup>®</sup> Patient Support by Sanofi Genzyme. CareASSIST offers access support for eligible patients prescribed ELITEK
CareASSIST<sup>®</sup> ELITEK<sup>®</sup> (rasburicase)

Resources and support for your eligible patients

CareASSIST offers access support for eligible patients prescribed ELITEK.

If your patients have commercial insurance, they may qualify for the CareASSIST Copay Program and pay as little as $0 out of
pocket for ELITEK. Learn more.

Access and Reimbursement

Access and Reimbursement

Assistance navigating the insurance process, including benefits investigations, claims assistance, and information about prior authorizations and appeals. 

SEE WHAT'S OFFERED

Financial Assistance

Financial Assistance

CareASSIST offers programs and services that can help eligible patients with the cost of ELITEK.

COMMERCIAL INSURANCE

NO INSURANCE

Access and Reimbursement

Resource Support

Information on independent support services for patients and caregivers, as well as product ordering and replacement information.

FIND SUPPORT

To learn more about CareASSIST

Explore the additional educational resources offered for ELITEK

FIND ELITEK RESOURCES HERE

IMPORTANT SAFETY INFORMATION

WARNING: HYPERSENSITIVITY REACTIONS, HEMOLYSIS, METHEMOGLOBINEMIA, AND INTERFERENCE WITH URIC ACID MEASUREMENTS

  • Hypersensitivity Reactions: ELITEK can cause serious and fatal hypersensitivity reactions including anaphylaxis. Immediately and permanently discontinue ELITEK in patients who experience a serious hypersensitivity reaction.
  • Hemolysis: Do not administer ELITEK to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Immediately and permanently discontinue ELITEK in patients developing hemolysis. Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting ELITEK.
  • Methemoglobinemia: ELITEK can result in methemoglobinemia in some patients. Immediately and permanently discontinue ELITEK in patients developing methemoglobinemia.
  • Interference with Uric Acid Measurements: ELITEK enzymatically degrades uric acid in blood samples left at room temperature. Collect blood samples in prechilled tubes containing heparin and immediately immerse and maintain sample in an ice water bath. Assay plasma samples within 4 hours of collection.

CONTRAINDICATIONS

ELITEK is contraindicated in patients with a history of anaphylaxis or severe hypersensitivity to rasburicase or in patients with development of hemolytic reactions or methemoglobinemia with rasburicase. ELITEK is contraindicated in individuals deficient in glucose-6-phosphate dehydrogenase (G6PD).

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥20%), when used concomitantly with anticancer therapy, are vomiting, nausea, fever, peripheral edema, anxiety, headache, abdominal pain, constipation, diarrhea, hypophosphatemia, pharyngolaryngeal pain, and increased alanine aminotransferase.

USE IN SPECIFIC POPULATIONS
  • Pregnancy: Consider the benefits and risks of ELITEK and possible risks to the fetus when prescribing ELITEK to a pregnant woman
  • Lactation: Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with ELITEK and for 2 weeks after the last dose

Please see full Prescribing Information, including Boxed WARNING.

MAT-US-2020415-v1.0-01/2021
Last Updated: January 2021-01-01YYYY